A multi-centre, randomised, double-blind, placebo-controlled, dose ranging study to evaluate the safety and efficacy of GSK2586184 in patients with chronic plaque psoriasis
Latest Information Update: 07 Jan 2024
At a glance
- Drugs Solcitinib (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 19 Jan 2016 Results published in the British Journal of Dermatology
- 30 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Apr 2014 Preliminary results reported in a Galapagos media release.